NCT04439929View on ClinicalTrials.gov

Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

July 17, 2019

Primary Completion Date

January 16, 2020

Study Completion Date

January 16, 2020

Conditions

Healthy Participants

Interventions

BIOLOGICAL

TUR01

Administered as a single 40 mg, subcutaneous dose

BIOLOGICAL

Adalimumab-EU

Administered as a single 40 mg, subcutaneous dose

Trial Locations (1)

14050

PAREXEL International GmbH, Early Phase Clinical Unit Berlin, Berlin

All Listed Sponsors

lead

Turgut İlaçları A.Ş.

INDUSTRY

NCT04439929 - Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects | Biotech Hunter | Biotech Hunter